Proactive - Interviews for investors

Ionic Rare Earths Ltd has reported a potential 30-50% reduction in the carbon footprint of its rare earth oxide (REO) production compared to conventional producers.

A preliminary Life Cycle Assessment (LCA) conducted by Minviro on the magnet recycling process of subsidiary Ionic Technologies has highlighted significant environmental benefits.

The results are undergoing peer review, with final findings expected in March 2025.

Ionic Technologies’ Belfast commercial recycling plant will focus on Didymium oxide ((NdPr)₂O₃) and Dysprosium oxide (Dy₂O₃), with additional analysis on Neodymium oxide (Nd₂O₃).

The study also assessed the environmental impact of applying IXR’s magnet REO products in direct drive wind turbine generators using Rare Earth Permanent Magnet (REPM) technology.

The company aims to support a more sustainable rare earth supply chain, particularly in Europe, reducing dependence on Chinese markets.

IXR is working with Less Common Metals and Ford Technologies to establish a UK-based recycled magnet supply chain, with Ford using these materials at its EV drive train facility in Halewood.

Ionic Rare Earths expects the final study results to reinforce the advantages of its patented process and strengthen its position in decarbonising rare earth supply chains.

#IonicRareEarths #RareEarths #MagnetRecycling #SustainableMining #ESG #CO2Reduction #Decarbonisation #ElectricVehicles #WindEnergy #GreenManufacturing #CircularEconomy #CriticalMinerals #NetZero #EnvironmentalImpact #CarbonFootprint #RenewableEnergy #SupplyChain #Recycling #AdvancedManufacturing #MiningInnovation

Asian Battery Metals PLC has identified priority drilling areas at the Oval Copper-Nickel Project in southwest Mongolia ahead of its Phase 3 exploration program, scheduled to begin next month.

The program will include up to 1,500 metres of diamond drilling, downhole electromagnetic (DHEM) surveys and regional geophysical surveys. Drilling will focus on untested or modified DHEM conductive plates identified from the Phase 2 exploration work.

Additionally, the company will investigate a high gravity inversion anomaly and conduct targeted exploration in six step-out drilling areas within the detailed exploration zone.

According to the company, the 2025 Phase 3 program aims to further assess the extent of magmatic copper and nickel sulphide mineralisation within the tenement.

The key objectives are to refine the understanding of the high-grade zone in the Oval gabbroic body, test deeper extensions of the intrusion based on geophysical data, and conduct scout drilling on additional anomalies.

#AsianBatteryMetals #MiningExploration #Copper #Nickel #Mongolia #Drilling #Geophysics #MineralExploration #DiamondDrilling #Phase3Exploration #BatteryMetals #ResourceDevelopment #MiningNews #Geology #ElectromagneticSurveys #GravityAnomalies #GabbroicIntrusion #SoilSampling #MagmaticMineralisation #MiningIndustry

Recce Pharmaceuticals Ltd (ASX:RCE, FSE: R9Q) director & chief medical advisor Dr Alan Dunton and executive chairman Dr John Prendergast talked with Proactive’s Tylah Tully about the company’s latest Phase 2 clinical trial results for RECCE® 327, a topical gel targeting Diabetic Foot Infections (DFIs) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

Dr Dunton explained that the Phase 2 study was conducted across three sites in Australia, testing the gel in 30 patients.

The results showed a 93% cure or improvement rate after two weeks of treatment, with 82% of patients responding positively within the first week.

He highlighted the gel’s strong efficacy, noting that unlike many antibiotics, R327G did not develop bacterial resistance.

Dr Prendergast emphasised that these findings provided confidence as Recce moved toward regulatory approval.

He revealed that the upcoming registration Phase 3 trial in Indonesia, originally planned for 300 patients, may achieve meaningful interim data in as few as 100 patients.

This could fast-track approval within a shorter timeframe, potentially 12 months.

Both executives underscored the clinical potential of R327G, particularly in tackling antibiotic-resistant infections.

With its first-in-class synthetic antibiotic properties, the gel could become a game-changer in infection treatment.

#ReccePharmaceuticals #ASXRCE #Biotech #ClinicalTrials #Recce327 #Antibiotics #DiabeticFootUlcer #ABSSSI #DrugDevelopment #MedicalResearch #StockMarket

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to discuss promising topline results from the company's Phase 1, single ascending dose trial of TNX-1500 in healthy participants. The trial evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 and was designed to support dosing for an upcoming Phase 2 trial in kidney transplant recipients.

Two published studies in the American Journal of Transplantation demonstrated that TNX-1500 can prevent rejection, prolong survival, and preserve graft function in non-human primate renal and heart allografts, either as a single agent or in combination with other therapies.

Dr. Lederman shared that Phase 1 results showed TNX-1500 at 10 mg/kg and 30 mg/kg doses effectively blocked both primary and secondary antibody responses to a test antigen. Pharmacokinetic data suggest that monthly dosing at 10 mg/kg or higher could be effective. These findings reinforce the company’s confidence in TNX-1500’s potential to prevent organ transplant rejection and improve graft survival with a lower long-term toxicity burden compared to existing immunosuppressive therapies.

Tonix plans to present these results to the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting. Pending FDA alignment, the company will move forward with a Phase 2 efficacy study in kidney transplant recipients.

#proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #TonixPharmaceuticals #Biotech #FDA #FDAApproval #TNX1500 #MonoclonalAntibodies #OrganTransplant #AutoimmuneDisease #MedicalResearch #PharmaNews #HealthcareInnovation

Ondo InsurTech PLC CEO Craig Foster talked with Proactive's Stephen Gunnion about the company’s continued expansion in the US, following the latest agreement with Privilege Underwriters Reciprocal Exchange (PURE). The high-net-worth insurer has expanded its use of Ondo’s LeakBot technology beyond its pilot in New York into six more states—Indiana, North Carolina, New Jersey, Ohio, Pennsylvania, and Washington.

Foster explained that PURE initially wanted to test the company’s customer service capabilities, given its clientele of affluent homeowners. He noted that Ondo has already proven its ability to meet high standards, having worked with UK-based high-net-worth insurers such as Hiscox.

Discussing the broader US expansion, Foster highlighted that this marks the latest partnership to scale up since Nationwide expanded LeakBot into 16 states. Ondo follows a state-by-state expansion model, securing lead partners in each new region before adding more insurers to drive further adoption.

Looking ahead, Foster will travel to Tennessee for a key industry think tank, a strategy inspired by Whisker Labs' success in growing its own home safety technology across the US. Foster emphasized that the company faces no direct competition in a $17 billion market, presenting a major opportunity for growth.

For more exclusive interviews, subscribe to Proactive’s YouTube channel, like the video, and enable notifications for updates.

#OndoInsurTech #LeakBot #USExpansion #InsuranceTech #HomeProtection #PUREInsurance #CraigFoster #ProactiveInvestors #WaterDamage #TechInnovation #InvestorUpdates

hVIVO PLC chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company’s newly inked £2 million contract with a biotech client. The deal will fund the final stage of hVIVO’s human metapneumovirus (hMPV) characterisation study, paving the way for future human challenge trials.

Khan explained that hVIVO had already completed a successful pilot study involving a small group of volunteers. The new study will expand the trial to a larger population to confirm infection levels and establish a robust challenge model for hMPV research.

“This, hopefully, if successful, will go a long way in accelerating the development of an hMPV vaccine,” Khan stated. He emphasised that there are currently no approved vaccines or treatments for hMPV, which has been gaining media attention due to its increasing prevalence in children.

The study, which was not included in hVIVO’s year-end sales pipeline, came as a new business opportunity in early 2025. hVIVO expects to complete the characterisation study by June, with commercial human challenge trials potentially beginning in the second half of the year.

Stay tuned for more updates on hVIVO’s research progress. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and enable notifications for more exclusive interviews.

#hVIVO #Biotech #hMPV #ClinicalTrials #VaccineResearch #MedicalInnovation #Healthcare #Investing #Pharmaceuticals #ProactiveInvestors

International Graphite (ASX: IG6) has completed successful purification test-work on graphite from its Springdale Graphite Project in Western Australia.

The test-work, coordinated by Japan’s Marubeni Corporation, achieved total graphitic carbon (TGC) purity of up to 99.97%, meeting lithium-ion battery anode specifications.

The bench-scale program used graphite concentrates from drilling and bulk concentrate extraction conducted in 2023. Further purification test-work is planned.

Marubeni, one of the world's largest integrated trading and investment conglomerates, is seeking to expand its access to critical minerals, including graphite, to support Japan’s battery and motor vehicle manufacturing industries.

Representatives from Marubeni recently visited the Springdale Graphite Project and the Collie Graphite Processing and R&D Facility to progress discussions on collaboration under the existing non-binding memorandum of understanding (MoU) between the companies.

This MoU covers potential graphite supply and financial support for International Graphite’s mine-to-market strategy.

International Graphite stated that partnering with Marubeni strengthens confidence in its assets and development strategy.

The company emphasised that Japan’s battery industry required new sources of graphite, and IG6 offered a secure and reliable Australian supply.

#InternationalGraphite, #Marubeni, #Graphite, #BatteryMaterials, #LithiumIon, #GraphitePurification, #SpringdaleGraphite, #CollieGraphite, #CriticalMinerals, #Mining, #AustraliaMining, #BatteryIndustry, #GraphiteProcessing, #ElectricVehicles, #EVBatteries, #MineralResources, #JapanIndustry, #GraphiteSupply, #MiningTechnology, #BatteryManufacturing

Recce Pharmaceuticals Ltd has received positive Phase II clinical trial results for RECCE® 327 Topical Gel (R327G) in treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including Diabetic Foot Infections (DFI).

The study achieved a 93% primary efficacy endpoint over 14 days, with an interim response rate of 86% at seven days. No serious adverse events were reported.

These results support Recce’s upcoming Phase III registrational study for DFI in Indonesia, which has been approved by the Indonesian Drug and Food Regulatory Authority.

An interim analysis is expected in 2025, with full trial completion anticipated by the end of the year. Recce will also advance to a Phase III trial for ABSSSI and DFI in Australia.

Recce aims for an accelerated commercialisation pathway by 2026. The global ABSSSI treatment market was valued at US$7.3 billion in 2018 and is projected to reach US$26 billion by 2032.

The trial followed FDA standards, using recognised diagnostic tools to assess treatment efficacy. The findings reinforce R327G’s potential as a broad-spectrum anti-infective to address antimicrobial resistance.

#ReccePharmaceuticals, #ClinicalTrials, #Phase2Trial, #Antibiotics, #AntimicrobialResistance, #SkinInfections, #DiabeticFootInfections, #MedicalResearch, #Pharmaceuticals, #Healthcare, #DrugDevelopment, #FDAApproval, #Biotech, #MedicalInnovation, #WoundCare, #R327G, #BacterialInfections, #PharmaIndustry, #AustraliaHealthcare, #GlobalHealth

D3 Energy Ltd (ASX: D3E, OTCQB: DNRGF) has been granted three new Technical Cooperation Permits (TCPs) adjacent to its flagship exploration permit ER315 in South Africa

The new permits, TCP258, TCP259 and TCP260, cover a combined area of more than 5,700 hectares, expanding the company’s exploration footprint in a key helium province.

These newly acquired TCPs provide additional low-cost exploration and appraisal opportunities. Previous appraisal work at ER315 has demonstrated promising results, with helium samples of up to 6.2% confirmed during production testing of multiple boreholes at shallow depths.

The TCPs are valid for one year and will involve low-cost desktop studies. Upon completion of these studies, D3 Energy may apply for Exploration Rights over the relevant areas.

#D3Energy, #HeliumExploration, #NaturalGas, #EnergyResources, #Mining, #ExplorationPermits, #ResourceDevelopment, #HeliumIndustry, #EnergySector, #Methane, #MiningInvestment, #GasExploration, #SustainableEnergy, #HeliumProduction, #ASX, #OTCQB, #ResourceExploration, #EnergyMarkets, #MiningTechnology, #ExplorationRights

Pantoro Ltd (ASX:PNR, OTC:PNTOF) managing director Paul Cmrlec talked with Proactive’s Tylah Tully about the company’s ongoing resource growth program at the Norseman Gold Project in Western Australia and the latest high-grade drilling results.

Cmrlec noted that Pantoro’s growth drilling campaign, which began last year with a 38,000-metre program, was progressing well.

The company is targeting multiple structures to optimise resource access, and so far, results have met expectations.

He confirmed that Pantoro was advancing the rehabilitation of the Bullen Decline, with underground drilling expected to commence in March.

Multiple drill rigs are already operational, supporting the company’s growth strategy.

Looking ahead, Pantoro plans to continue drilling non-stop for the next couple of years, with four underground drill rigs expected on-site soon.

The focus remains on expanding through the Scotia area, with a goal of establishing two additional underground mines.

Cmrlec emphasised that alongside expansion, Pantoro remains committed to maintaining strong cash flow and delivering operational success.

#Pantoro #ASXPNR #GoldMining #NorsemanGoldProject #DrillingResults #GoldExploration #MiningNews #WesternAustralia #ProactiveInvestors